methyl 2-(4-phenylbicyclo[2.2.2]octan-1-yl)acetate | 70631-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-phenylbicyclo[2.2.2]octan-1-yl)acetate
• 英文别名: methyl (4-phenylbicyclo[2.2.2]oct-1-yl)acetate；methyl 2-(4-phenyl-1-bicyclo[2.2.2]octanyl)acetate
• CAS: 70631-58-2
• 化学式: C₁₇H₂₂O₂
• 分子量: 258.36
• InChiKey: DAUYILCHZOCLQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-phenylbicyclo[2.2.2]octan-1-yl)acetate 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 [bis(trifluoroacetoxy)iodo]benzene 、 碘 、 potassium acetate 作用下， 以 氯仿 、 二甲基亚砜 为溶剂， 反应 4.5h， 生成 methyl 2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)bicyclo[2.2.2]octan-1-yl)acetate
  参考文献：
  名称：

  Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687)

  摘要：

  A new series of pyrazinecarboxamide DGAT1 inhibitors was designed to address the need for a candidate drug with good potency, selectivity, and physical and DMPK properties combined with a low predicted dose in man. Rational design and optimization of this series led to the discovery of compound 30 (AZD7687), which met the project objectives for potency, selectivity, in particular over ACAT1, solubility, and preclinical PK profiles. This compound showed the anticipated excellent pharmacokinetic properties in human volunteers.

  DOI：

  10.1021/jm301296t
• 作为产物：
  描述：

  4-(甲氧羰基)双环[2.2.2]辛烷-1-羧酸 在 aluminum (III) chloride 、 草酰氯 、 溴 、 silver benzoate 、 三乙胺 、 N,N-二甲基甲酰胺 、 mercury(II) oxide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 14.67h， 生成 methyl 2-(4-phenylbicyclo[2.2.2]octan-1-yl)acetate
  参考文献：
  名称：

  LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

  摘要：

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。

  公开号：

  US20140200215A1

文献信息

• [EN] CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190<br/>[FR] COMPOSÉS CARBAMOYLES COMME INHIBITEURS DE DGAT1 190
  申请人：ASTRAZENECA AB

  公开号：WO2009081195A1

  公开（公告）日：2009-07-02

  DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

  DGAT-1抑制剂化合物公式(I)，药用可接受的盐和前药，以及药物组合物、制造它们的过程以及它们在治疗例如肥胖症中的用途，其中，例如，环A是可选取代的2,6-吡嗪二基；X是=O；环B是可选取代的1,4-苯基；Y1是直接键或-O-；Y2是-(CH2)r-，其中r是2或3；n是0或当Y1是环B和环C之间的直接键并且当环B是1,4-苯基和环C是(4-6C)环烷时，n是1；环C是可选取代的(4-6C)环烷、(7-10C)双环烷、(8-12C)三环烷、苯基或吡啶二基；L是直接键或-O-；p是0、1或2，并且当p是1或2时，RA1和RA2各自独立地为氢或(1-4C)烷基；Z是羧酸或其模拟物或生物等排体。
• Carbamoyl Compounds as DGAT1 Inhibitors 190
  申请人：Bauer Udo Andreas

  公开号：US20090298853A1

  公开（公告）日：2009-12-03

  DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is ═O; Ring B is optionally substituted 1,4-phenylene; Y 1 is a direct bond or —O—; Y 2 is —(CH 2 ) r — wherein r is 2 or 3; n is 0 or n is 1 when Y 1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or —O—; p is 0, 1 or 2 and when p is 1 or 2 R A1 and R A2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

  本文介绍了公式（I）的DGAT-1抑制剂化合物，其药学上可接受的盐和前药，以及制备它们的制药组合物、制备过程和用于治疗肥胖等疾病的用途。其中，例如，环A是可选取代的2,6-吡唑二基；X是 ═O；环B是可选取代的1,4-苯基；Y1是直接键或—O—；Y2是—（CH2）r—，其中r为2或3；当Y1是环B和环C之间的直接键时，n为0或1，当环B是1,4-苯基，环C是（4-6C）环烷基时，n为1；环C是可选取代的（4-6C）环烷基，（7-10C）双环烷基，（8-12C）三环烷基，苯基或吡啶二基；L是直接键或—O—；p为0、1或2，当p为1或2时，RA1和RA2各自独立地为氢或（1-4C）烷基；Z为羧基或其类似物或生物同位素。
• Pyrimido [4,5-B] -Oxazines For Use as Dgat Inhibitors
  申请人：Birch Alan Martin

  公开号：US20080306059A1

  公开（公告）日：2008-12-11

  Compounds of formula (I) or salts thereof, wherein A, and R 1 to R 5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  化合物公式（I）或其盐，其中A和R1至R5如规范中所定义，是DGAT-1抑制剂，因此在治疗肥胖等方面非常有用。本文还描述了制备化合物公式（I）的过程。
• Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
  申请人：AstraZeneca AB

  公开号：US07749997B2

  公开（公告）日：2010-07-06

  Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  式(I)的化合物或其盐，其中A和R1至R5如规范所定义，是DGAT-1抑制剂，因此在治疗肥胖症等方面有用。还描述了制备式(I)化合物的过程。
• Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors
  申请人：AstraZeneca AB

  公开号：US08017603B2

  公开（公告）日：2011-09-13

  Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.

  公式（I）的化合物或其盐，其中A和R1至R5如规范所定义，是DGAT-1抑制剂，因此在治疗肥胖等方面是有用的。本文还描述了制备公式（I）化合物的过程。